Literature DB >> 18205270

Relationship and significance between anti-beta2-glycoprotein I antibodies and platelet activation state in patients with ulcerative colitis.

Yan-Hang Gao1, Pu-Jun Gao, Chun-Guang Wang, Xiao-Cong Wang, Yun-Feng Piao.   

Abstract

AIM: To study the relationship between anti-beta2-glycoprotein I (abeta2GPI) antibodies and platelet activation state in patients with ulcerative colitis (UC) and its significance.
METHODS: Peripheral blood samples were collected from 56 UC patients (34 males and 22 females, aged 43.5 years, range 21-66 years), including 36 at active stage and 20 at remission stage, and 25 sex-and age-matched controls. The level of abeta2GPI was measured by ELISA. The platelet activation markers, platelet activation complex-I (PAC-I) and P-selectin (CD62P) were detected by flow cytometry.
RESULTS: The A value for IgG abeta2GPI in the active UC group was 0.61 +/- 0.13, significantly higher than that in the remittent UC and control groups (0.50 +/- 0.13 and 0.22 +/- 0.14, P < 0.01). There was a significant difference between the two groups (P < 0.01). The A value for IgM abeta2GPI in the active and remittent UC groups was 0.43 +/- 0.13 and 0.38 +/- 0.12, significantly higher than that in the control group (0.20 +/- 0.12, P < 0.01). However, there was no significant difference between the two groups (P > 0.05). The PAC-I positive rate for the active and remittent UC groups was 30.6% +/- 7.6% and 19.6% +/- 7.8% respectively, significantly higher than that for the control group (6.3% +/- 1.7%, P < 0.01). There was a significant difference between the two groups (P < 0.01). The CD62P positive rate for the active and remittent UC groups was 45.0% +/- 8.8% and 31.9% +/- 7.8% respectively, significantly higher than that for the control group (9.2% +/- 2.7%, P < 0.01). There was a significant difference between the two groups (P < 0.01). In the active UC group, the more severe the state of illness was, the higher the A value for IgG abeta2GPI was, and the positive rate for PAC-I and CD62P was positively correlated with the state of illness (Fabeta2GPI = 3.679, P < 0.05; FPAC-I (%) = 5.346, P < 0.01; and FCD62P (%) = 5. 418, P < 0.01). Meanwhile, in the same state of illness, the A value for IgG abeta2GPI was positively correlated to the positive rates for PAC-I and CD62P.
CONCLUSION: abeta2GPI level, platelet activation state and their relationship of them are closely correlated with the pathogenesis and development of UC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205270      PMCID: PMC2684007          DOI: 10.3748/wjg.14.771

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Antiphospholipid antibodies and thrombosis.

Authors:  M Greaves
Journal:  Lancet       Date:  1999-09-18       Impact factor: 79.321

2.  Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis.

Authors:  R K Linskens; A A van Bodegraven; M Schoorl; H A Tuynman; P Bartels
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 3.  Experimental thrombosis and antiphospholipid antibodies: new insights.

Authors:  S S Pierangeli; A E Gharavi; E N Harris
Journal:  J Autoimmun       Date:  2000-09       Impact factor: 7.094

4.  Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease.

Authors:  Koichiro Sonoda; Satoshi Ikeda; Yohei Mizuta; Yoshiyuki Miyahara; Shigeru Kohno
Journal:  J Gastroenterol       Date:  2004-10       Impact factor: 7.527

5.  Hemostatic imbalance in active and quiescent ulcerative colitis.

Authors:  A A van Bodegraven; M Schoorl; J P Baak; R K Linskens; P C Bartels; H A Tuynman
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

Review 6.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

7.  Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I.

Authors:  A A Manfredi; P Rovere; S Heltai; G Galati; G Nebbia; A Tincani; G Balestrieri; M G Sabbadini
Journal:  Arthritis Rheum       Date:  1998-02

8.  The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.

Authors:  M L Bertolaccini; T Atsumi; A Escudero Contreras; M A Khamashta; G R Hughes
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

9.  Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; E Anagnostopoulou; H Kritikos; I A Mouzas; E A Kouroumalis; O N Manousos
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

10.  Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant.

Authors:  T A Brighton; P J Hogg; Y P Dai; B H Murray; B H Chong; C N Chesterman
Journal:  Br J Haematol       Date:  1996-04       Impact factor: 6.998

View more
  1 in total

1.  Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.

Authors:  Bilgehan Yüzbaşıoğlu; Müge Ustaoğlu; Şule Yüzbaşıoğlu; Ulaş Emre Akbulut; Kamil Özdil
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.